Patents by Inventor Gerald WILLIMSKY

Gerald WILLIMSKY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • High avidity HPV T-cell receptors
    Patent number: 11401316
    Abstract: The present invention pertains to novel high avidity antigen recognizing constructs against Human Papilloma Virus antigens. The invention provides novel T cell receptor (TCR) based molecules which are selective and specific for HPV 16/18 proteins E5, E6 and E7. The TCR of the invention, and HPV antigen-binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of HPV infection, as well as for the diagnosis, treatment and prevention of HPV infection mediated secondary diseases as HPV infection caused cancers, such as cervical, nasopharyngeal or head and neck cancer. Further provided are nucleic acids encoding the proteins of the invention, and recombinant cells expressing the same.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 2, 2022
    Assignee: MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
    Inventors: Thomas Blankenstein, Gerald Willimsky
  • T CELL RECEPTORS FOR TUMOR SPECIFIC PROTEASOME SPLICE VARIANTS AND USES THEREOF
    Publication number: 20210061876
    Abstract: The present invention pertains to antigen recognizing constructs against tumor specific proteasome splicing variants. The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for tumor cells carrying antigenic epitopes generated by proteasome peptide splicing of tumor specific antigens. The TCRs of the invention, and antigen binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of proliferative diseases, preferably for the treatment of cancer. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.
    Type: Application
    Filed: January 2, 2019
    Publication date: March 4, 2021
    Applicants: Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts, Imperial College Innovations Limited, Charité - Universitätsmedizin Berlin
    Inventors: Thomas BLANKENSTEIN, Gerald WILLIMSKY, Juliane LIEPE, Peter Michael KLOETZEL, Michele MISHTO, Christin BEIER
  • Tumor specific T-cell receptors
    Patent number: 10683336
    Abstract: The present invention relates to a method for the production of novel T-cell receptors (TCR) which provide a reduced risk of adverse events in immune therapy, specifically in adoptive T cell transfer. The TCRs produced according to the method of the invention are specific for tumor cells and do not react with healthy tissue. Furthermore provided are nucleic acids encoding the TCR of the invention, vectors and host cells comprising the TCRs of the invention as well as their use is the treatment of tumorous diseases.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: June 16, 2020
    Assignee: Max-Delbrüeck-Centrum Für Molekulare Medizin (MDC) Berlin-Buch
    Inventors: Thomas Blankenstein, Gerald Willimsky
  • HIGH AVIDITY HPV T-CELL RECEPTORS
    Publication number: 20190062398
    Abstract: The present invention pertains to novel high avidity antigen recognizing constructs against Human Papilloma Virus antigens. The invention provides novel T cell receptor (TCR) based molecules which are selective and specific for HPV 16/18 proteins E5, E6 and E7. The TCR of the invention, and HPV antigen-binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of HPV infection, as well as for the diagnosis, treatment and prevention of HPV infection mediated secondary diseases as HPV infection caused cancers, such as cervical, nasopharyngeal or head and neck cancer. Further provided are nucleic acids encoding the proteins of the invention, and recombinant cells expressing the same.
    Type: Application
    Filed: October 13, 2016
    Publication date: February 28, 2019
    Inventors: Thomas BLANKENSTEIN, Gerald WILLIMSKY
  • TUMOR SPECIFIC T-CELL RECEPTORS
    Publication number: 20150307585
    Abstract: The present invention relates to a method for the production of novel T-cell receptors (TCR) which provide a reduced risk of adverse events in immune therapy, specifically in adoptive T cell transfer. The TCRs produced according to the method of the invention are specific for tumor cells and do not react with healthy tissue. Furthermore provided are nucleic acids encoding the TCR of the invention, vectors and host cells comprising the TCRs of the invention as well as their use is the treatment of tumorous diseases.
    Type: Application
    Filed: November 29, 2013
    Publication date: October 29, 2015
    Inventors: Thomas BLANKENSTEIN, Gerald WILLIMSKY